Can You Safely Take Painkillers for IBS?

Most over-the-counter painkillers people reach for first, particularly ibuprofen and other anti-inflammatory drugs, are among the worst choices for irritable bowel syndrome. IBS pain does not originate from the kind of tissue inflammation that these drugs target, and their side effects can make gut symptoms worse. Opioid painkillers are even more problematic, to the point that gastroenterology guidelines explicitly warn against prescribing them for IBS. Safe and effective pain relief for IBS does exist, but it looks different from what most people expect.

Why Typical Painkillers Miss the Mark in IBS

IBS pain behaves differently from a headache, a sprained ankle, or arthritis. Those involve local inflammation or tissue damage that anti-inflammatory drugs can directly address. IBS pain, by contrast, is now understood to be driven largely by changes in how the central nervous system processes signals coming from the gut, a phenomenon researchers call central sensitization. The brain and spinal cord essentially turn up the volume on normal gut sensations, so that stretching or contracting that would not normally register as painful starts to hurt. Brain imaging studies have identified altered pain-modulation circuits, changes in brain connectivity, and shifts in neurotransmitter levels that help explain why the pain persists even when the gut looks structurally normal.

This matters for painkiller choices because a drug designed to reduce inflammation at the site of an injury does not address a pain-processing problem in the brain and spinal cord. And the overlap between IBS, anxiety, and depression (with odds of co-occurrence roughly four times higher than in the general population) further underscores that IBS pain has deep roots in central nervous system function, not just in what is happening locally in the intestines.¹

The Problem With NSAIDs

Nonsteroidal anti-inflammatory drugs like ibuprofen, naproxen, and aspirin are the painkillers most people grab from the medicine cabinet. For IBS, they create a frustrating paradox: they do not address the central pain-processing issue, and they can actively damage the gut lining. NSAIDs work by blocking enzymes involved in inflammation, but those same enzymes help maintain the protective mucus layer in the stomach and intestines. Regular NSAID use can lead to increased intestinal permeability, sometimes called “leaky gut” in casual terms, and can trigger or worsen diarrhea, cramping, and bloating.

Research has found that people with IBS tend to use NSAIDs more frequently than people without IBS, and that this higher exposure may be clinically relevant, though whether NSAIDs contribute to IBS onset or people with IBS simply take more painkillers for their symptoms remains an open question.² There is also a separate but related concern: NSAID use is an independent risk factor for microscopic colitis, a condition that causes chronic watery diarrhea and can be mistaken for or co-exist with IBS. One study found that NSAID use roughly tripled the odds of developing microscopic colitis, and when NSAIDs were combined with proton pump inhibitors (acid-reducing drugs many IBS patients also take), the risk increased roughly fivefold.³

Acetaminophen (paracetamol) is gentler on the gut lining than NSAIDs and does not carry the same intestinal risks. For occasional pain unrelated to IBS, like a headache on a bad day, acetaminophen is a reasonable choice. But it does little for the visceral, cramping abdominal pain characteristic of IBS, because that pain is not driven by the pathways acetaminophen affects.

Why Opioids Are Off the Table

Opioid painkillers such as codeine, oxycodone, and tramadol might seem appealing for severe IBS pain, but they are the single most dangerous painkiller category for people with this condition. The American Gastroenterological Association’s clinical practice update states flatly that opioids should not be prescribed for chronic gastrointestinal pain from disorders of gut-brain interaction, including IBS.⁴

The reasons go beyond the well-known constipation that opioids cause. There is a condition called narcotic bowel syndrome in which chronic opioid use paradoxically makes abdominal pain worse. The pain escalates with continued or increasing doses, trapping patients in a cycle where the drug they take for pain becomes the primary driver of it. This happens because opioids alter central nervous system pain processing, and in someone whose pain circuits are already sensitized (as they are in IBS), the result can be a dramatic worsening rather than relief.⁵ The abdominal pain in narcotic bowel syndrome is thought to be centrally mediated, distinct from the peripheral side effects like bloating, nausea, and constipation that opioids also produce, though both problems can occur simultaneously.⁶

Opioids also disrupt the gut microbiome. They damage the epithelial barrier, alter inflammatory signaling, and allow non-native bacterial populations to proliferate, a specific form of dysbiosis that can feed back into pain and gut dysfunction.⁷ NSAIDs also shift microbiome composition, meaning both major categories of conventional painkillers can destabilize a gut ecosystem that is already fragile in IBS.⁸

Antispasmodics as First-Line Relief

If conventional painkillers are poorly suited to IBS, what actually helps? For the cramping, spasmodic pain that many people with IBS experience, antispasmodic drugs are the most direct option. These work by relaxing the smooth muscle of the intestinal wall, reducing the contractions that cause cramping. Expert guidance identifies antispasmodics as playing a central role in managing functional abdominal cramping pain.⁹

Several antispasmodics are used worldwide, including hyoscine (sold over the counter in many countries as Buscopan), mebeverine, pinaverium, otilonium, and alverine. They work through slightly different mechanisms but share the goal of calming intestinal muscle spasms. A review of the evidence found that multiple agents in this class reduced pain and improved bowel symptoms in placebo-controlled trials.¹⁰ However, there is an honest caveat here: a later analysis of antispasmodic options available in North America found the supporting data limited in quality, with small sample sizes, short treatment durations, and inconsistent outcome measures making it hard to compare them against the more rigorously tested FDA-approved IBS medications.¹¹

Despite the limitations of the evidence base, antispasmodics remain widely used because they target the actual mechanism of cramping pain, work relatively quickly, and have a mild side-effect profile. They are a pragmatic choice for episodic flares rather than daily maintenance, and many IBS patients keep them on hand for particularly painful days.

Low-Dose Antidepressants as Pain Modulators

One of the most counterintuitive but well-supported treatments for IBS pain involves antidepressants, specifically tricyclic antidepressants (TCAs) like amitriptyline at doses far lower than those used for depression. These are not prescribed because IBS is “all in your head.” They work because IBS pain involves altered signaling in the brain and spinal cord, and these drugs modify exactly those pathways. The pain-reducing effect appears to come from changes to gastrointestinal motility and visceral pain processing rather than any mood-related action at the low doses used.¹²

The evidence for TCAs is substantial. A meta-analysis found that low-dose TCAs produced a large and statistically significant reduction in abdominal pain scores compared to placebo.¹³ An updated meta-analysis pooling data across different classes of these gut-brain neuromodulators confirmed the benefit: TCAs reduced the risk of pain not improving by roughly 30% compared to placebo, and serotonin-norepinephrine reuptake inhibitors showed an even larger effect in a smaller number of trials.¹⁴

The choice of neuromodulator depends partly on the type of IBS. TCAs tend to slow gut transit, making them a better fit for diarrhea-predominant IBS. Selective serotonin reuptake inhibitors (SSRIs) like fluoxetine or sertraline can help when anxiety and hypervigilance around gut sensations are a major part of the picture, but they are not effective for abdominal pain specifically and may actually cause diarrhea as a side effect.¹⁵ SSRIs can help constipation-predominant IBS by speeding things up, but if pain relief is your primary goal, a TCA is the better-studied option.

Prescription Pain Options Designed for the Gut

While standard opioids are off-limits, pharmaceutical development has produced drugs that borrow selectively from opioid pharmacology without the systemic risks. Eluxadoline is a prescription medication approved specifically for IBS with diarrhea. It acts on opioid receptors in the gut but is designed to stay peripheral, combining activation of some receptors with blockade of others in a way that slows gut transit and reduces pain without the central nervous system effects and addiction potential of traditional opioids. In two large phase 3 trials, eluxadoline outperformed placebo for the composite endpoint of reduced pain and improved stool consistency, with the benefit sustained over six months at the higher dose.¹⁶

A closer look at pain specifically showed that about 39% of eluxadoline patients achieved at least a 50% improvement in daily abdominal pain compared to about 33% on placebo, a modest but real advantage.¹⁷ Eluxadoline is not appropriate for everyone. It carries warnings for people without a gallbladder and those who drink heavily due to a risk of pancreatitis. But it illustrates an important principle: the future of IBS pain treatment lies in drugs designed for the gut-brain axis, not in repurposing general painkillers.

Peppermint Oil and Pregabalin

Peppermint oil is one of the oldest remedies for gut discomfort that actually has clinical trial data behind it. Its active ingredient, L-menthol, blocks calcium channels in intestinal smooth muscle, producing an antispasmodic effect from a botanical source. A meta-analysis of seven randomized controlled trials found that peppermint oil was roughly twice as likely as placebo to improve global IBS symptoms, and about 1.8 times as likely to reduce abdominal pain specifically.¹⁸ Enteric-coated capsules are preferred over drinking peppermint tea because the coating allows the oil to reach the intestines before dissolving, reducing the risk of heartburn that can occur when menthol relaxes the lower esophageal sphincter.

Pregabalin, a drug originally developed for nerve pain and epilepsy, has shown preliminary promise for visceral hypersensitivity in IBS. Early research found it could normalize pain thresholds in the gut without desensitizing normal sensation, effectively turning down the “volume” on pain signals without numbing the gut entirely.¹⁹ Larger confirmatory studies are still needed, and pregabalin carries sedation and dependence risks that limit its casual use, but it represents another avenue for people whose IBS pain has not responded to first-line options.

Brain-Gut Behavioral Therapies

The fact that IBS pain is centrally driven opens a treatment door that many people do not expect: psychological therapies that directly target the pain circuits. This is not about telling patients their pain is imaginary. It is about using structured techniques to change how the brain processes gut signals. Both European and North American gastroenterology guidelines now recommend cognitive behavioral therapy and gut-directed hypnotherapy as second-line treatments for IBS.²⁰

A network meta-analysis comparing various brain-gut behavioral therapies found that self-guided or minimal-contact cognitive behavioral therapy, face-to-face multicomponent behavioral therapy, and face-to-face gut-directed hypnotherapy all significantly reduced abdominal pain compared to controls, with risk ratios ranging from about 0.71 to 0.77, meaning roughly a quarter fewer patients had persistent pain after treatment.²¹ Digital gut-directed hypnotherapy delivered through an app has also shown benefit for both pain and stool symptoms, making these approaches more accessible than they once were.²²

Behavioral therapies are particularly attractive because they produce lasting changes without any of the gastrointestinal side effects that plague pharmacological options. They work well alongside medication rather than competing with it. The main barriers are cost, access to trained therapists, and the time commitment involved, though digital programs are rapidly lowering those barriers.

Sex Differences in Treatment Response

IBS affects women roughly twice as often as men, and the differences go beyond prevalence. Research has documented sex-based differences in gut transit time, visceral sensitivity, and central pain processing, along with specific effects of estrogen and progesterone on gut function. Clinical trials have also found gender differences in how well patients respond to certain drug therapies.²³ Some IBS medications, including alosetron (for severe diarrhea-predominant IBS), were initially studied or approved primarily for women because the treatment effect was more pronounced in female patients.

Hormonal fluctuations also complicate the picture. Many women with IBS report that symptoms flare around menstruation, which means a painkiller strategy that works mid-cycle may be inadequate during a period. This overlaps with another issue: endometriosis, which can cause chronic pelvic and abdominal pain, is frequently misdiagnosed as IBS for years before a correct diagnosis is reached. If your IBS pain is cyclical and concentrated in the lower abdomen, it is worth raising the possibility of endometriosis with your doctor, since the management strategies differ substantially.

Cannabinoid Research

Preclinical research has begun exploring whether noneuphorigenic cannabinoids, meaning compounds from the cannabis plant that do not produce a high, could help with visceral pain. A recent study using animal models relevant to IBS abdominal pain found that specific combinations of cannabinoids, including cannabidiol (CBD), produced dose-dependent reductions in visceromotor responses to gut distension and showed synergistic potential for modulating visceral sensation.²⁴ This is still animal-model work, and there are no human clinical trials establishing CBD as an effective IBS pain treatment. The unregulated CBD products widely available at retail vary enormously in quality and actual cannabinoid content, so self-treating IBS with CBD supplements is getting ahead of the science.

That said, the cannabinoid receptor system is heavily represented in both the gut and the brain’s pain circuits, making it a logical therapeutic target. Whether this translates into a practical treatment option will depend on rigorous human trials that have not yet been completed.

A Practical Framework for Managing IBS Pain

Given the range of options and the clear risks of the usual suspects, a reasonable approach to IBS pain works through layers rather than reaching for the strongest painkiller available:

• For cramping flares: Enteric-coated peppermint oil or an antispasmodic like hyoscine can provide relatively quick relief for episodic cramping without systemic risk.
• For persistent pain: A low-dose tricyclic antidepressant, titrated gradually with your doctor, has the strongest evidence for sustained abdominal pain reduction in IBS, particularly if diarrhea is also a problem.
• For anxiety-driven symptoms: An SSRI may help the vigilance and worry that amplify gut sensations, though it will not target pain directly and may worsen diarrhea.
• For IBS-D specifically: Eluxadoline offers a gut-targeted approach that addresses both pain and stool urgency.
• Alongside any medication: Cognitive behavioral therapy or gut-directed hypnotherapy changes how the brain processes gut pain at its source, with effects that outlast the treatment period.

The drugs that do not belong in an IBS pain toolkit are the ones most readily available: ibuprofen and its NSAID relatives damage the gut lining and do not address visceral pain processing, while opioids risk narcotic bowel syndrome and microbiome disruption. Acetaminophen is safe enough for unrelated aches but contributes nothing meaningful to IBS-specific pain. If you find yourself repeatedly reaching for over-the-counter painkillers to get through IBS flares, that is a signal to talk to a gastroenterologist about switching to treatments designed for the condition rather than continuing to manage it with drugs that were never built for visceral pain.